Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.150
-0.210 (-4.82%)
At close: Feb 27, 2026, 4:00 PM EST
4.300
+0.150 (3.61%)
After-hours: Feb 27, 2026, 5:57 PM EST
Neuphoria Therapeutics Employees
As of June 30, 2025, Neuphoria Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,873,342
Profits / Employee
-$707,989
Market Cap
22.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 8 | 0 | - | 7 | 1 |
| Jun 30, 2024 | 8 | - | - | 8 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| IO Biotech | 78 |
| Vistagen Therapeutics | 59 |
| Cue Biopharma | 41 |
| Senti Biosciences | 34 |
| Daré Bioscience | 23 |
| Skye Bioscience | 16 |
| Reviva Pharmaceuticals Holdings | 14 |
NEUP News
- 2 months ago - Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees - GlobeNewsWire
- 3 months ago - Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium - GlobeNewsWire
- 3 months ago - Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions - GlobeNewsWire
- 3 months ago - Neuphoria Therapeutics Inc. Sends Letter to Stockholders - GlobeNewsWire
- 3 months ago - Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value - GlobeNewsWire
- 4 months ago - Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process - GlobeNewsWire
- 4 months ago - PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 4 months ago - Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder - GlobeNewsWire